Will This Covid Star Get a Second Act?
Bloomberg Businessweek|March 21 - 28, 2022 (Double Issue)
Vir scored with monoclonal antibodies in the pandemic’s early days. Now it needs more
By Angelica Peebles. Illustration by Sujin Kim
Will This Covid Star Get a Second Act?

Vir Biotechnology Inc. started five years ago with an unconventional plan to tackle infectious diseases, for which pharmaceutical companies had shown little interest in researching new medicines. The emergence of Covid-19 presented the San Francisco-based biotech with an opportunity to make good on its promise. It rapidly designed a monoclonal antibody therapy that worked after other new drugs failed. At one point, Vir’s treatment was the only one of its kind that was effective against the heavily mutated omicron variant, helping fuel the sale of almost 2 million doses of its drug to date.

That success may not last, though. Vir’s own research suggests its Covid drug, sotrovimab, isn’t as potent against the newest mutation of omicron, known as BA.2. The arrival of pills from Pfizer Inc. and Merck & Co. to treat Covid means the medical community may migrate away from anti bodies such as Vir’s anyway. Sotrovimab is difficult to administer because it must be given by infusion in a medical center. And cases of Covid are dwindling, cutting into the market for any new antivirals.

After an impressive drug development debut that led Vir to a $3 billion market valuation, its management must prove the company can live up to its hype and churn out blockbusters for some of the world’s other most prevalent illnesses, including hepatitis B, HIV, and influenza. It has been difficult to devise drugs against them in part because the viruses that cause them mutate rapidly.

Diese Geschichte stammt aus der March 21 - 28, 2022 (Double Issue)-Ausgabe von Bloomberg Businessweek.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der March 21 - 28, 2022 (Double Issue)-Ausgabe von Bloomberg Businessweek.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BLOOMBERG BUSINESSWEEKAlle anzeigen
Instagram's Founders Say It's Time for a New Social App
Bloomberg Businessweek US

Instagram's Founders Say It's Time for a New Social App

The rise of AI and the fall of Twitter could create opportunities for upstarts

time-read
4 Minuten  |
March 13, 2023
Running in Circles
Bloomberg Businessweek US

Running in Circles

A subscription running shoe program aims to fight footwear waste

time-read
3 Minuten  |
March 20 - 27, 2023
What I Learned Working at a Hawaiien Mega-Resort
Bloomberg Businessweek US

What I Learned Working at a Hawaiien Mega-Resort

Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.

time-read
10 Minuten  |
March 20 - 27, 2023
How Noma Will Blossom In Kyoto
Bloomberg Businessweek US

How Noma Will Blossom In Kyoto

The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking

time-read
3 Minuten  |
March 20 - 27, 2023
The Last-Mover Problem
Bloomberg Businessweek US

The Last-Mover Problem

A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps

time-read
10+ Minuten  |
March 20 - 27, 2023
Tick Tock, TikTok
Bloomberg Businessweek US

Tick Tock, TikTok

The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban

time-read
10+ Minuten  |
March 20 - 27, 2023
Cleaner Clothing Dye, Made From Bacteria
Bloomberg Businessweek US

Cleaner Clothing Dye, Made From Bacteria

A UK company produces colors with less water than conventional methods and no toxic chemicals

time-read
3 Minuten  |
March 20 - 27, 2023
Pumping Heat in Hamburg
Bloomberg Businessweek US

Pumping Heat in Hamburg

The German port city plans to store hot water underground and bring it up to heat homes in the winter

time-read
3 Minuten  |
March 20 - 27, 2023
Sustainability: Calamari's Climate Edge
Bloomberg Businessweek US

Sustainability: Calamari's Climate Edge

Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment

time-read
4 Minuten  |
March 20 - 27, 2023
New Money, New Problems
Bloomberg Businessweek US

New Money, New Problems

In Naples, an influx of wealthy is displacing out-of-towners lower-income workers

time-read
4 Minuten  |
March 20 - 27, 2023